Bayesian study designs for new drug development in early-stage cancer clinical trials.
| Project/Area Number |
24500345
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Statistical science
|
|---|
| Research Institution | Kyoto University (2013-2014)
Yokohama City University (2012) |
|---|
Principal Investigator |
MORITA Satoshi 京都大学, 医学(系)研究科(研究院), 教授 (60362480)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
DAIMON Takashi 兵庫医科大学, 教授 (40372156)
TERAMUKAI Satoshi 京都府立医科大学, 教授 (20359798)
TOI Masakazu 京都大学, 大学院医学研究科, 教授 (10207516)
|
|---|
| Research Collaborator |
THALL Peter F. University of Texas M.D. Anderson Cancer Center, 教授
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | バイオマーカー / 個別化医療 / ベイズ流統計学 / 臨床腫瘍学 |
|---|
| Outline of Final Research Achievements |
We have developed novel study designs for phase I and phase II clinical trials aiming to boost new drug developments. We have proposed a new statistical approach to appropriately combine historical data into a current phase I clinical trial in which the safety of a new study treatment is evaluated. In addition, we have proposed to integrate biomarker data to design a phase II clinical trial to efficiently develop a stratified therapy. We will use our proposed methods in actual clinical trials.
|
Report
(4 results)
Research Products
(9 results)
